Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

New CAR T-Cell Therapy Approvals Diversify Treatment Options in Large B-Cell Lymphoma

March 18th 2021

Matthew Lunning, DO, discusses discussed the findings from pivotal CAR T-cell therapy trials in LBCL, the potential to utilize these agents in the outpatient setting, how off-the-shelf allogeneic products could further transform outcomes, and the importance of shortening brain-to-vein time for this patient population.

Incidence of TA-TMA

March 18th 2021

Parameswaran Hari, MD, reviews challenges in defining the incidence of transplant-associated thrombotic microangiopathy; an expert panel comments on the volume of autologous transplants performed in expert centers.

Overview of Transplant-Associated Thrombotic Microangiopathy (TA-TMA)

March 18th 2021

Jeffrey Laurence, MD, provides an overview of transplant-associated thrombotic microangiopathy (TA-TMA), the associated risk factors, and the role of the complement pathway in TA-TMA development.

Dr. Stone on the Promise of Menin Inhibitors in AML

March 17th 2021

Richard M. Stone, MD, discusses the promise of menin inhibitors in patients with acute myeloid leukemia.

Dr. Majhail on the Importance of Utilizing Social Media in Oncology

March 17th 2021

Navneet Majhail, MD, MS, discusses the importance of utilizing social media in oncology.

Dr. Cutler on the Toxicity Profile of Belumosudil in cGVHD

March 17th 2021

Corey S. Cutler, MD, MPH, FRCPC, discusses the toxicity profile of belumosudil in patients with chronic graft-versus-host disease.

Real-World Data Showcase Favorable Outcomes and Less Toxicity With Axi-Cel in Large B-Cell Lymphoma

March 17th 2021

The real-world utilization of axicabtagene ciloleucel demonstrated favorable outcomes and less frequent toxicity events compared with those reported in the pivotal ZUMA-1 trial and other real-world studies.

GTB-3550 TriKE Reduces Bone Marrow Blast Levels in High-Risk MDS, Relapsed/Refractory AML

March 17th 2021

The trispecific killer cell engager product GTB-3550 was found to result in up to a 63.7% reduction in bone marrow blast levels in patients with high-risk myelodysplastic syndromes and relapsed/refractory acute myeloid leukemia.

Pembrolizumab Approved in Europe for Adult and Pediatric Relapsed/Refractory Classical Hodgkin Lymphoma

March 17th 2021

The European Commission has approved an expanded label for pembrolizumab for use as a single agent in the treatment of select adult and pediatric patients aged 3 years and older who have relapsed/refractory classical Hodgkin lymphoma.

Emerging Therapeutic Options in Polycythemia Vera

March 17th 2021

What to look forward to in the polycythemia vera space, including new clinical trials.

Real-World Use of Ruxolitinib in Polycythemia Vera

March 17th 2021

Experts give real-world insight in using ruxolitinib in patients with polycythemia vera.

Dr. Cutler on the Efficacy Results of the ROCKstar Study in cGVHD

March 16th 2021

Corey S. Cutler, MD, MPH, FRCPC, discusses the efficacy results of the ongoing phase 2 ROCKstar trial in patients with chronic graft-versus-host disease.

Dr. Giralt on the Potential Utility of Omidubicel in Hematologic Malignancies

March 16th 2021

Sergio A. Giralt, MD, discusses the potential utility of omidubicel in hematologic malignancies.

Narsoplimab Elicits Responses Across High-Risk HSCT-TMA Subtypes

March 16th 2021

The MASP-2 inhibitor narsoplimab demonstrated high response rates and a significant improvement in laboratory markers and organ function irrespective of subgroup in adult patients with high-risk hematopoietic stem cell transplant–associated thrombotic microangiopathy.

Liso-Cel Administration in Relapsed/Refractory LBCL Successful in Inpatient, Outpatient Settings at Nonuniversity Centers

March 16th 2021

Lisocabtagene maraleucel was successfully administered in patients with relapsed/refractory aggressive large B-cell lymphoma who were at nonuniversity medical centers in both the outpatient and inpatient settings through the use of standard operating procedures and multidisciplinary teams

Ruxolitinib Induces Prolonged Efficacy in Steroid-Refractory Acute GVHD

March 16th 2021

Ruxolitinib has demonstrated sustained efficacy with a lower probability of progression or additional systemic therapeutics in patients with steroid-refractory acute graft-versus-host disease.

AB-205 Shows Tolerability, Robust Effects in Patients With Lymphoma Undergoing HDT-ASCT

March 16th 2021

The engineered cord endothelial cell product AB-205 showed an encouraging safety profile along with robust effects in eliminating oral/gastrointestinal severe regimen-related toxicities in patients with systemic lymphoma undergoing high-dose therapy and autologous hematopoietic stem cell transplantation.

Camidanlumab Tesirine Under Investigation in Relapsed/Refractory Hodgkin Lymphoma

March 16th 2021

The safety and efficacy of the antibody-drug conjugate camidanlumab tesirine is under investigation in patients with relapsed/refractory Hodgkin lymphoma as part of a phase 2 clinical trial, which recently completed accrual.

Frontline Axi-Cel Elicits 74% CR Rate in High-Risk Large B-Cell Lymphoma

March 15th 2021

Axicabtagene ciloleucel elicited a high objective response rate of 85%, with a complete response rate of 74% when used as a first-line therapy in patients with high-risk large B-cell lymphoma.

Risk-Adapted CAR T Dosing Maintains Efficacy, Improves Safety in Pediatric Relapsed/Refractory ALL

March 15th 2021

A risk-adapted CD19 CAR T-cell therapy dosing approach allowed pediatric patients with relapsed/refractory acute lymphocytic leukemia to maintain a high rate of remission, while reducing the risk of severe toxicities among those with a high initial disease burden